Objective: The purpose of this study was to determine whether the recommended waiting period of 3 months is necessary for repeat fine-needle aspiration biopsy (FNAB). Study Design: A retrospective review of 128 nodules from 126 patients with initial nondiagnostic (ND) results was performed for the period between January 2009 and December 2012. Demographic and clinical factors were recorded including age, sex, time interval between FNABs, and ultrasound (US) factors, i.e. nodule size, location, consistency, suspicious malignant findings and thyroiditis. The time interval was subdivided into </≥5, 10, 15 and 20 weeks after the initial FNAB. The effects on the nuclear atypia were analyzed using the Fisher exact test and the Mann-Whitney U test. Results: None of the demographic, clinical or US variables was significantly related to the atypical diagnosis of repeat FNAB. The time interval until repeat FNAB was also not related to the atypical diagnosis (p = 0.63, 0.57, 0.23 and 0.48 for 5, 10, 15 and 20 weeks, respectively). Conclusion: The timing of repeat FNAB for thyroid nodules with previous ND results did not increase the nuclear atypia on repeat FNAB.

Keywords:
Thyroid nodules, Repeat fine-needle aspiration, Nuclear atypia
1.
Baloch ZW, Cibas ES, Clark DP, et al: The National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference: a summation. Cytojournal 2008;5:6.
2.
Kini SR: Specimen adequacy and assessment, reporting system; in Pine J, McGough J (eds): Thyroid Cytopathology: An Atlas and Text. Philadelphia, Lippincott Williams & Wilkins, 2008, pp 17-26.
3.
Gharib H, Papini E, Paschke R, et al: American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2010;16(suppl 1):1-43.
4.
Cooper DS, Doherty GM, Haugen BR, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
5.
LiVolsi VA, Merino MJ: Worrisome histologic alterations following fine-needle aspiration of the thyroid (WHAFFT). Pathol Annu 1994;29:99-120.
6.
Recavarren RA, Houser PM, Yang J: Potential pitfalls of needle tract effects on repeat thyroid fine-needle aspiration. Cancer Cytopathol 2013;121:155-161.
7.
Singh RS, Wang HH: Timing of repeat thyroid fine-needle aspiration in the management of thyroid nodules. Acta Cytol 2011;55:544-548.
8.
Lubitz CC, Nagarkatti SS, Faquin WC, et al: Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy. Thyroid 2012;22:590-594.
9.
Nagarkatti SS, Faquin WC, Lubitz CC, et al: Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol 2013;20:60-65.
10.
Renshaw AA: Should ‘atypical follicular cells' in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol 2010;118:186-189.
11.
Renshaw AA: Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy. Cancer Cytopathol 2011;119:322-327.
12.
Olson MT, Clark DP, Erozan YS, Ali SZ: Spectrum of risk of malignancy in subcategories of ‘atypia of undetermined significance'. Acta Cytol 2011;55:518-525.
13.
Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA: The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio. A proposed performance measure for reporting in The Bethesda System for Thyroid Cytopathology. Cancer Cytopathol 2012;120:111-116.
14.
Horne MJ, Chhieng DC, Theoharis C, et al: Thyroid follicular lesion of undetermined significance: evaluation of the risk of malignancy using the two-tier sub-classification. Diagn Cytopathol 2012;40:410-415.
15.
Moon WJ, Jung SL, Lee JH, et al: Benign and malignant thyroid nodules: US differentiation - a multicenter retrospective study. Radiology 2008;247:762-770.
16.
Kim DW, Eun CK, In HS, Kim MH, Jung SJ, Bae SK: Sonographic differentiation of asymptomatic diffuse thyroid disease from normal thyroid: a prospective study. AJNR Am J Neuroradiol 2010;31:1956-1960.
17.
Ersöz C, Soylu L, Erkoçak EU, Tetiker T, Gümürdülü D: Histologic alterations in the thyroid gland after fine-needle aspiration. Diagn Cytopathol 1997;16:230-232.
18.
Polyzos SA, Patsiaoura K, Zachou K: Histological alterations following thyroid fine needle biopsy: a systematic review. Diagn Cytopathol 2009;37:455-465.
19.
Krane JF, Nayar R, Renshaw AA: Atypical cells of undetermined significance; in Ali SZ, Cibas ES (eds): The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. New York, Springer, 2010, pp 37-49.
20.
Choi YS, Hong SW, Kwak JY, Moon HJ, Kim EK: Clinical and ultrasonographic findings affecting nondiagnostic results upon the second fine needle aspiration for thyroid nodules. Ann Surg Oncol 2012;19:2304-2309.
21.
Choi YJ, Baek JH, Ha EJ, et al: Differences in risk of malignancy and management recommendations in subcategories of thyroid nodules with atypia of undetermined significance or follicular lesion of undetermined significance: the role of ultrasound-guided core-needle biopsy. Thyroid 2014;24:494-501.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.